Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
$0.01
+6.1%
$0.01
$0.00
$0.04
N/AN/A135,541 shs250,437 shs
GEOVF
Genovis AB (publ.)
$7.34
$7.34
$7.34
$8.28
N/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
$0.04
-40.6%
$0.05
$0.01
$0.10
N/AN/A14,877 shs17,342 shs
TRSBF
3SBio
$4.59
+9.8%
$3.26
$2.22
$4.74
N/AN/A1,657 shs575 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
+6.14%0.00%+47.56%+53.16%+19.81%
GEOVF
Genovis AB (publ.)
0.00%0.00%0.00%0.00%0.00%
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
0.00%-20.67%-37.41%-38.07%-13.90%
TRSBF
3SBio
0.00%+17.69%+41.23%+454.41%+498.28%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
GEOVF
Genovis AB (publ.)
N/AN/AN/AN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
0.00
N/AN/AN/A
GEOVF
Genovis AB (publ.)
0.00
N/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
0.00
N/AN/AN/A
TRSBF
3SBio
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/A
GEOVF
Genovis AB (publ.)
N/AN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
$665.45KN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/A0.00N/AN/AN/AN/AN/A
GEOVF
Genovis AB (publ.)
N/AN/A0.00N/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/A0.00N/AN/AN/AN/A8/20/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/A
GEOVF
Genovis AB (publ.)
N/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/A
GEOVF
Genovis AB (publ.)
N/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/A
TRSBF
3SBio
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
7N/AN/ANot Optionable
GEOVF
Genovis AB (publ.)
N/AN/AN/ANot Optionable
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
2N/AN/ANot Optionable
TRSBF
3SBio
5,411N/AN/ANot Optionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

180 Life Sciences stock logo

180 Life Sciences NASDAQ:ATNFW

$0.01 +0.00 (+6.14%)
As of 08/1/2025 02:41 PM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Genovis AB (publ.) OTC:GEOVF

$7.34 0.00 (0.00%)
As of 12/2/2022

Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for generating a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; and GingisKHAN, a cysteine protease that digests human IgG1 at a specific site above the hinge. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally to arginine residues; and IgGZERO (EndoS), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes N-linked glycans in the Fc-region of native IgG. Further, it provides IgGZERO LE, an endoglycosidase acting on complex type N-glycans from Streptococcus pyogenes; deGlycIT, an IgGZERO (EndoS) enzyme for agarose beads for deglycosylation of Fc-glycans; GlycINATOR an endoglycosidase from Streptococcus pyogenes that hydrolyzes the all glycoforms structure; and GlycINATOR (EndoS2), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes glycans at the Fc glycosylation site of IgG. Additionally, the company offers GlyCLICK, a site-specific conjugation technology used for IgG on enzymatic remodeling of the Fc glycans and click chemistry; SialEXO, a sialidase product for the removal and analysis of sialic acids; enzymes for O-glycans; and antibody fragmentation services, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. The company has a collaboration with Waters Corporation. Genovis AB (publ.) was founded in 1999 and is based in Lund, Sweden.

60 Degrees Pharmaceuticals stock logo

60 Degrees Pharmaceuticals NASDAQ:SXTPW

$0.04 -0.02 (-40.57%)
As of 07/31/2025 03:57 PM Eastern

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

3SBio OTCMKTS:TRSBF

$4.59 +0.41 (+9.81%)
As of 07/31/2025 12:36 PM Eastern

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium. In addition, the company provides MN709 Minoxidil Foam and Nalfuraphine hydrochloride tablets. Further, it provides trading, project management and consultation, technology, sports, financial, investment advisory, as well as manufactures medical devices; and offers agricultural services. The company has collaboration agreements with companies, such as Toray. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.